Metastatic Prostate Cancer at Diagnosis Has a Better Prognosis Than Recurrent Disease - Renal and Urology News

-

Men who have metastatic prostate cancer (PCa) at initial presentation are less likely to die from the malignancy compared with men who progress to metastatic PCa after initial therapy, according to a new study.

The finding suggest that “these entities may have distinct biology informed by prior treatment exposure,” Hala T. Borno, MD, of the University of California, San Francisco, and collaborators concluded in a report published in Urologic Oncology.

The study examined data from 14,753 patients in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry diagnosed with PCa from 1990 to 2016. Of these, 669 (5%) had metastatic disease: 303 (45%) at diagnosis (de novo metastatic PCa) and 366 (55%) who progressed to metastatic disease after initial therapy (recurrent metastatic PCa).

The median follow-up time was 40 months for men with de novo metastatic PCa compared with 22 months for those with recurrent metastatic PCa. Among the patients with metastatic disease at diagnosis, 21 (10%) received initial local therapy and 272 (90%) received initial hormonal therapy. Among patients who progressed to metastatic disease, 239 (65%) received initial local therapy and 127 (35%) received initial systematic hormonal therapy.

Continue Reading

After adjusting for sociodemographic factors, diagnosis year, comorbidities, and marital status, patients with metastatic disease at diagnosis had a significant 34% lower risk of cancer-specific mortality than those who progressed to metastatic disease (P =.002), the investigators reported. The investigators found no difference in the stratified analysis between men who received combined local and hormonal therapy compared with local therapy alone.

“These data support the notion that local management may not confer a survival benefit in an unselected population of patients with metastatic disease,” the authors wrote.

Dr Borno and colleagues concluded that their data “contribute to the growing literature characterizing the role of local therapy as part of an evolving treatment landscape for advanced disease.”

Reference

Borno HT, Cowan JE, Zhao S, et al. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. Urol Oncol. Published online August 8, 2020. doi:10.1016/j.urolonc.2020.07.012

Topics:

Prostate Cancer


Comments

Post a Comment

Popular posts from this blog

I Wish I Didn't Need an Oncologist at All, But I'm Thankful for the One ...

-
Image
efudex side effects :: Article Creator Inmates Given Ivermectin In Jail Will Each Get $2,000 After Settlement Your browser is not supporteddetroitnews.Com detroitnews.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on detroitnews.Com Efudex Cream Efudex Cream Generic Name & Formulations General Description Fluorouracil 5%. Pharmacological Class Antimetabolite. How Supplied Soln (w. Drop dispenser)—10mL, 25mL; Crm—40g Efudex Cream Indications Indications Multiple actinic or solar keratoses. Superficial basal cell carcinoma when conventional therapy is impractical (5% only); see full labeling. Efudex Cream Dosage and Administration Adult Keratoses: Apply twice daily until eros
Read more

Early symptoms of cancer in males: Common warning signs

-
Image
fluciclovine f 18 :: Article Creator The U.S. Navy Might Be Done With The F/A-18 Super Hornet Fighter Will The U.S. Navy Receive Its Final F/A-18 Super Hornets? - Around the holidays, money can be tight, a fact that the United States Navy has also learned as its negotiations to buy the last batch of Super Hornets are reportedly stalled over the growing price tag. USNI News reported on Tuesday that the contract for the U.S. Navy to purchase the final twenty F/A-18 E/F Super Hornets from aerospace giant Boeing appears to be at a standstill. The Navy continues to work with Boeing on the contract for the 20 congressionally added Super Hornet aircraft. Ongoing contract negotiations cannot be discussed at this time," Capt. Michael Burks, the program manager for the F/A-18 and EA-18G office at Naval Air Systems Command, told USNI News in a statement. Previous estimates put the unit cost of the final batch of aircraft at $55.7 million, and la
Read more

20 Famous Men Who Have Had Prostate Cancer

-
Image
leukemia treatment options :: Article Creator Current And Breakthrough Treatments For Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the immune system. Because it's slow-growing, many people with CLL won't need to start treatment for many years after their diagnosis. Once the cancer begins to grow, there are many available treatment options that can help people achieve remission. This means people can experience long periods of time when there's no sign of cancer in their bodies. The exact treatment option that you'll receive depends on a variety of factors. This includes: whether your CLL is symptomatic the stage of the CLL, based on results of blood tests and a physical exam your age your overall health While there's no cure for CLL yet, breakthroughs in the field are on the horizon. Doctors typically stage CLL using a system called the Rai system. Low
Read more